Analysts expect Eli Lilly and Company (NYSE:LLY) to report earnings of $1.08 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Eli Lilly and’s earnings, with estimates ranging from $1.06 to $1.11. Eli Lilly and reported earnings of $0.95 per share in the same quarter last year, which indicates a positive year over year growth rate of 13.7%. The firm is scheduled to report its next earnings report on Tuesday, January 30th.

According to Zacks, analysts expect that Eli Lilly and will report full year earnings of $4.21 per share for the current year, with EPS estimates ranging from $4.14 to $4.25. For the next financial year, analysts anticipate that the company will post earnings of $4.65 per share, with EPS estimates ranging from $4.52 to $4.84. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Eli Lilly and.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period last year, the business posted $0.88 earnings per share.

Several brokerages have issued reports on LLY. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 5th. Jefferies Group restated a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a research report on Thursday, August 31st. Leerink Swann raised their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a research report on Wednesday. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $105.00 price objective (up from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. Eli Lilly and has a consensus rating of “Hold” and a consensus price target of $90.25.

Shares of Eli Lilly and (NYSE LLY) opened at $86.54 on Friday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The stock has a market cap of $95,330.00, a P/E ratio of 21.15, a price-to-earnings-growth ratio of 1.76 and a beta of 0.35. Eli Lilly and has a 1 year low of $71.76 and a 1 year high of $89.09.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. The ex-dividend date is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a dividend yield of 2.60%. Eli Lilly and’s dividend payout ratio (DPR) is currently 99.05%.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $85.14, for a total transaction of $16,602,300.00. Following the transaction, the insider now directly owns 123,513,247 shares in the company, valued at $10,515,917,849.58. The disclosure for this sale can be found here. Insiders have sold 651,088 shares of company stock worth $56,439,586 over the last ninety days. Insiders own 0.20% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in LLY. Parametric Portfolio Associates LLC increased its stake in Eli Lilly and by 6.2% in the third quarter. Parametric Portfolio Associates LLC now owns 2,107,356 shares of the company’s stock valued at $180,263,000 after acquiring an additional 123,300 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in Eli Lilly and in the third quarter valued at approximately $916,000. Public Employees Retirement System of Ohio increased its stake in Eli Lilly and by 0.4% in the third quarter. Public Employees Retirement System of Ohio now owns 684,533 shares of the company’s stock valued at $58,555,000 after acquiring an additional 2,452 shares during the last quarter. Garde Capital Inc. bought a new position in Eli Lilly and in the third quarter valued at approximately $202,000. Finally, Archford Capital Strategies LLC increased its stake in Eli Lilly and by 26.2% in the third quarter. Archford Capital Strategies LLC now owns 8,076 shares of the company’s stock valued at $690,000 after acquiring an additional 1,676 shares during the last quarter. 76.42% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Company (LLY) Expected to Announce Earnings of $1.08 Per Share” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/eli-lilly-and-company-lly-expected-to-announce-earnings-of-1-08-per-share/1768770.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.